Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials

1. Patients with moderate-to-severe plaque psoriasis treated with ixekizumab had significantly greater improvements in psoriasis compared to those treated with placebo at the end...

Pembrolizumab for the treatment of advanced melanoma

1. For patients with unresectable melanoma or metastatic melanoma that progressed despite treatment, pembrolizumab treatment resulted in objective response rate of 33%, 12-month progression-free...

Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses

  1. Adjunctive TMP-SMX therapy in patients with cutaneous abscesses resulted in a significantly higher clinical cure rates compared to placebo. 2. Adjunctive TMP-SMX therapy...

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

1. Women diagnosed with melanoma during pregnancy or within 1 year of delivery were significantly more likely to have metastatic or recurrent disease. 2. Women diagnosed...

Trials demonstrate effective antibody-based treatment for psoriasis: AMAGINE-2 and 3 Study

1. Brodalumab was more effective than either placebo or ustekinumab at reducing the severity of psoriasis after 12 weeks of treatment. 2. Consistent dosing of...

Anti-interleukin-17A therapy shows promise in psoriatic arthritis

1. Among patients with psoriatic arthritis, secukinumab was superior to placebo at week 24 in terms of ACR20 response, which captures a 20% decrease...

Vemurafenib linked to therapeutic effect in various cancers

1. Participants with BRAF V600 mutation-positive small-cell lung cancer, Erdheim Chester Disease (ECD) and Langerhan’s-Cell Histiocytosis (LCH) demonstrated a modest but statistically significant response...

High incidence of uveitis in patients with psoriatic disease

  1. Patients with psoriasis and psoriatic disease were more likely to have uveitis and vice versa. Evidence Rating Level: 2 (Good) Study Rundown: Psoriasis is an...

Combination trametinib and dabrafenib show fewer side effects for metastatic melanoma than dabrafenib alone

1. In patients undergoing treatment for metastatic melanoma, there was a statistically significant decreased risk of cutaneous toxic effects in those patients who were...

Promising phase 2 results for new plaque psoriasis therapy

1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha therapy.  Evidence Rating Level: 1...
licensing as small

Popular